Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosis

Summary Pyrazinamide resistance is largely unknown in the spectrum of drug resistant phenotypes. We summarize data on PZA resistance in clinical isolates from South Africa. PZA DST should be performed when considering its inclusion in treatment of patients with rifampicin-resistant TB or MDR-TB.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Tuberculosis (Edinburgh, Scotland) Scotland), 2016-07, Vol.99, p.128-130
Hauptverfasser:	Whitfield, M.G, Streicher, E.M, Dolby, T, Simpson, J.A, Sampson, S.L, Van Helden, P.D, Van Rie, A, Warren, R.M
Format:	Artikel
Sprache:	eng
Schlagworte:	Antitubercular Agents - therapeutic use DNA sequencing Drug Resistance, Multiple, Bacterial - genetics Genotype Humans Infectious Disease Microbial Sensitivity Tests Mutation Mycobacterium tuberculosis Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - genetics Mycobacterium tuberculosis - pathogenicity Phenotype pncA gene Prevalence Pulmonary/Respiratory Pyrazinamide Pyrazinamide - therapeutic use South Africa - epidemiology Tuberculosis, Multidrug-Resistant - diagnosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - epidemiology Tuberculosis, Multidrug-Resistant - microbiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Pyrazinamide resistance is largely unknown in the spectrum of drug resistant phenotypes. We summarize data on PZA resistance in clinical isolates from South Africa. PZA DST should be performed when considering its inclusion in treatment of patients with rifampicin-resistant TB or MDR-TB.
ISSN:	1472-9792 1873-281X
DOI:	10.1016/j.tube.2016.05.003